Veloxis Pharmaceuticals A/S

Equities

VELO

DK0060048148

Delayed Nasdaq Copenhagen Other stock markets			5-day change	1st Jan Change
- ^DKK	-.--%		-.--%	-0.50%

2024	Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	CI
2022	Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	CI

Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call

Published on 2019-11-25 at 04:00

Presentation Operator Message
Operator (Operator)

Ladies and gentlemen, thank you for standing by, and welcome to the Veloxis conference call. [Operator Instructions] I must advise you that this

This article is reserved for subscribers

Unlock the article : SUBSCRIBE!

Already a customer? Log In

Latest news about Veloxis Pharmaceuticals A/S

Veloxis Pharmaceuticals A/S Selects to Present At the 2024 American Transplant Congress in Philadelphia	24-05-30	CI
Veloxis Pharmaceuticals Announces Dosing of the First Patient by partner Xenikos in the Global Phase 3 Study Evaluating T-Guard(R) in Patients with Steroid-Refractory Acute Graft-Versus-Host Disease (SR-aGVHD)	22-06-28	CI
Veloxis Pharmaceuticals, Inc entered into a global license agreement to acquire Worldwide Rights to FR104 from OSE Immunotherapeutics SA.	21-04-25	CI
Veloxis Pharmaceuticals A/S Announces Board Appointments	20-02-17	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from OMX Nordic All-Share Index	20-02-07	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	20-01-30	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) dropped from S&P Global BMI Index	20-01-30	CI
Asahi Kasei Pharma Denmark A/S completed the acquisition of Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others.	20-01-13	CI
Asahi Kasei Pharma Denmark A/S, Veloxis Pharmaceuticals A/S - M&A Call	19-11-25
Asahi Kasei Pharma Denmark A/S entered into a transaction agreement to acquire Veloxis Pharmaceuticals A/S from Novo Holdings A/S, Lundbeckfond Invest A/S, Board of Directors of Veloxis Pharmaceuticals, Executive Management of Veloxis Pharmaceuticals including Craig Collard and Ira Duarte, Carsten Nielsen and others for DKK 9.2 billion.	19-11-24	CI
Veloxis Pharmaceuticals A/S, Q3 2019 Earnings Call, Nov 13, 2019	19-11-13
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Third Quarter Ended September 30, 2019	19-11-12	CI
Veloxis Pharmaceuticals A/S Increases Earnings Guidance for 2019	19-10-30	CI
Veloxis Pharmaceuticals A/S(CPSE:VELO) added to S&P Global BMI Index	19-09-23	CI
Veloxis Pharmaceuticals A/S, Q2 2019 Earnings Call, Aug 09, 2019	19-08-09
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Second Quarter Ended June 30, 2019	19-08-09	CI
Veloxis Pharmaceuticals Revises Outlook for Full Year 2019	19-07-22	CI
Veloxis Pharmaceuticals A/S Reports Earnings Results for the First Quarter Ended March 31, 2019	19-05-08	CI
Veloxis Pharmaceuticals A/S, Q1 2019 Earnings Call, May 07, 2019	19-05-07
Veloxis Pharmaceuticals Provides Earnings Guidance for the Full Year 2019	19-05-06	CI
Veloxis Pharmaceuticals A/S, 2018 Earnings Call, Feb 28, 2019	19-02-28
Veloxis Pharmaceuticals A/S Reports Earnings Results for the Full Year Ended December 31, 2018	19-02-27	CI
Veloxis Pharmaceuticals A/S Announces the Promotion of Mark Hensley to Chief Commercial Officer	19-01-02	CI
FDA Approves New Indication for Envarsus XRA (Tacrolimus Extended-ReleaseTablets)	18-12-19	CI
Veloxis Pharmaceuticals A/S, Q3 2018 Earnings Call, Nov 15, 2018	18-11-15

Chart Veloxis Pharmaceuticals A/S

Duration

Period

VELO: Dynamic Chart

Company Profile

Sector

More about the company